About
We are the only eye care technology accelerator focused exclusively on medical devices, therapeutics, and consumer products
What we do
Take promising eye care technologies buried in institutions and drive them toward commercialization.
Why we do it
Ocular diseases are prevalent and feared by a large majority of the population – many even consider them worse than cancer or dementia. We want to be a part of solving this accelerating problem in the modern world.
Why us
With deep expertise and strong connections in the eye care industry, no other team has the same ability to fuel new eye care innovations and ready them for the marketplace.
The Facts
Ocular diseases are becoming more common worldwide than ever before
Over 1.3 billion people are affected by cataracts [1]
76 million people have glaucoma [2]
Nearly 300 million people suffer from AMD [3]
150 million people suffer from diabetic retinopathy [4]
2.7 billion people have myopia, and its prevalence will double to 50% of the population by 2050 [5]
Presbyopia affects more than 2 billion people [6]
[1] World Health Organization. (2019). World Report on Vision. Retrieved from WHO’s website
[2] World Health Organization. (2019). World Report on Vision. Retrieved from WHO’s website
[3] American Academy of Ophthalmology. Age-Related Macular Degeneration (AMD) Facts. https://www.aao.org/eye-health/diseases/amd-macular-degeneration. Accessed August 13, 2024.
[4] International Agency for the Prevention of Blindness (IAPB). (2020). Vision Atlas. Retrieved from IAPB Vision Atlas
[5] Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006.
[6] International Agency for the Prevention of Blindness (IAPB) and Brien Holden Vision Institute. (2016). Global Prevalence of Presbyopia and Its Economic Impact. Retrieved from IAPB’s Vision Atlas.
Discover
Our streamlined sourcing process and deep technical understanding unearths high-potential technologies that address large unmet patient needs in substantial markets.
Validate
We have the expertise to successfully develop these technologies and leverage market opportunities to their fullest potential. Our deep understanding and systematic process enable us to pinpoint critical market needs, identify areas for innovation, and ensure technical feasibility.
Build
Our team's extensive 100 + years of life science experience and connections streamline capital fundraising, reduce risk, and enhance value creation.
Exit
Together, we can help patients worldwide while seeking an exceptional return on investment.
The Team
A team of commercialization and start-up veterans
Our comprehensive industry expertise spans across the globe and includes 100+ years in eye care, biotech, product development, manufacturing, and more.
Robin G. Sears, MBA
Executive Chairman
Brad Beasecker, CFA
Chief Financial Officer
Mark Puwal
Chief Operating Officer
Paul Grimm
Operating Executive
Gordon Bethwaite
Operating Executive
Jayne Frilling
Project Coordinator
Our Partners
Collaborate with us to turn novel eye care technologies into life changing solutions
I’m an Investor
By becoming a shareholder in our portfolio of subsidiary companies, you become part of developing cutting-edge solutions for the future of eye care with the opportunity and potential for significant financial gain.**
I’m an Inventor
Bring your research to life through a fine-tuned eye care technology commercialization process that will set you on a track toward recognition and success. By partnering with our team, your idea has the highest probability of financial and regulatory success.
Our Companies
SANNT Operating Companies